eoadjuvant radiation therapy concurrent with S-1 followed by systemic S-1/Gemcitabine therapy for Borderline resectable pancreatic cancer patients; A pilot study
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000008888
- Lead Sponsor
- Department of Surgical Oncology and Gastroenterological Surgery, Sapporo Medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
1) Patients who have previously administered S-1 or gemcitabine 2) Patients who have previous history of radiotherapy to the abdomen 3) Uncontrollable watery or chornic diarrhea 4) Regular use of frucitocin, fenitoin or warfarin 5) Patients who can' t receive neither iodic drug because of drug allergy 6) Lung fibrosis or interstitial pneumonia which accompanied by clinical symptoms or are evident in imaging findings 7) Massive pleural or abdominal effusion 8) Those with Active infectious diseases 9) Uncontrolled diabetes 10) Simultaneous or metachronous (within 3 years) double cancers 11) Hemorrhagic peptic ulcer 12) Severe complications 13) Patients requiring systemic steroids medication 14) Severe mental disorders 15) Severe drug hypersensitivity 16) Pregnant or lactating women, or women with known or suspected pregnancy and men who want let to pregnancy 17) Patients seems inadequate for this study by investigators 18) Treatment history of a collagen disease or undergoing medical treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method completion rate
- Secondary Outcome Measures
Name Time Method R0 resection rate , pathological response rate , survival rate, Response rate, adverse effect